| Nr. | Year OPEN | Title | users say> | rate good | rate bad | no link | Citation |
Lung (Neoplasm)CetuximabColon and rectum (Neoplasia)BevacizumabORL (Neoplasia)ErlotinibLapatinibPanitumomabGefitinibReceptor (EGF)BortezomibPemetrexed| 1 | 2009 | EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. | 
| + | - | nl | Biologics 3(-):215-24 (2009) |
| 2 | 2009 | Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. | 
| + | - | nl | Health Technol Assess 13 Suppl 1(-):49-54 (2009) |
| 3 | 2007 | Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. | 
| + | - | nl | Health Technol Assess 11(12):1-128, iii-iv (2007) |
| 4 | 2007 | Cetuximab: clinical results in colorectal cancer. | 
| + | - | nl | Ann Oncol 18 Suppl 6(-):vi8-10 (2007) |
| 5 | 2007 | Cetuximab in squamous cell head and neck carcinomas. | 
| + | - | nl | Ann Oncol 18 Suppl 6(-):vi5-7 (2007) |
| 6 | 2011 | The nuclear epidermal growth factor receptor signaling network and its role in cancer. | 
| + | - | nl | Discov Med 12(66):419-32 (2011) |
| 7 | 2005 | Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. | 
| + | - | nl | Oncologist 10(4):282-91 (2005) |